Cited by 105Neonatal and Maternal InfectionsBacterial Infections and VaccinesStreptococcal Infections and Treatments

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016

Open access

Kobayashi, Miwako, Schrag, Stephanie J., Alderson, Mark R., Madhi, Shabir A., Baker, Carol J., Sobanjo-ter Meulen, Ajoke, Kaslow, David C., Smith, Peter G., Moorthy, Vasee S., Vekemans, Johan·2019·Vaccine

DOI 10.1016/j.vaccine.2016.12.029PMC PMC6892266

Open this paper in CoChat — free account Open PDF

Abstract

Globally, group B Streptococcus (GBS) remains a leading cause of sepsis and meningitis in infants in the first 90days of life. Intrapartum antibiotic prophylaxis (IAP) for women at increased risk of transmitting GBS to their newborns has been effective in reducing part, but not all, of the GBS disease burden in many high income countries (HICs). In low- and middle-income countries (LMICs), IAP use is low. Immunization of pregnant women with a GBS vaccine represents an alternative strategy to protecting newborns and young infants, through transplacental antibody transfer and potentially by reducing new vaginal colonization. This vaccination strategy was first suggested in the 1970s and several potential GBS vaccines have completed phase I/II clinical trials. During the 2015 WHO Product Development for Vaccines Advisory Committee meeting, GBS was identified as a high priority for the development of a vaccine for maternal immunization because of the major public health burden posed by GBS in LMICs, and the high technical feasibility for successful development. Following this meeting, the first WHO technical consultation on GBS vaccines was held on the 27th and 28th of April 2016, to consider development pathways for such vaccines, focused on their potential role in reducing newborn and young infant deaths and possibly stillbirths in LMICs. Discussion topics included: (1) pathophysiology of disease; (2) current gaps in the knowledge of global disease burden and serotype distribution; (3) vaccine candidates under development; (4) design considerations for phase III trials; and (5) pathways to licensure, policy recommendations and use. Efforts to address gaps identified in each of these areas are needed to establish the public health need for, the development and deployment of, efficacious GBS vaccines. In particular, more work is required to understand the global disease burden of GBS-associated stillbirths, and to develop quality-assured standardized antibody assays to identify correlates of protection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2016.12.029

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005
Phares, C. R. (2008) · JAMA · doi:10.1001/jama.299.17.2056 · Cited by 883
Correlation of Maternal Antibody Deficiency with Susceptibility to Neonatal Group B Streptococcal Infection
Baker, C. J., & Kasper, D. L. (1976) · New England Journal of Medicine · doi:10.1056/nejm197604012941404 · Cited by 676
Self-citation
Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis
Edmond, K. M., Kortsalioudaki, C., Scott, S., Schrag, S. J., Zaidi, A. K., Cousens, S., & Heath, P. T. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61651-6 · Cited by 600
Self-citation
Epidemiology of Group B Streptococcal Disease in the United States: Shifting Paradigms
Schuchat, A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.3.497 · Cited by 600
The infectious origins of stillbirth
Goldenberg, R. L., & Thompson, C. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/s0002-9378(03)00470-8 · Cited by 344
Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: Experience in the United States and implications for a potential group B streptococcal vaccine
Schrag, S. J., & Verani, J. R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.056 · Cited by 314
Self-citation
Revisiting the Need for Vaccine Prevention of Late-Onset Neonatal Group B Streptococcal Disease
Jordan, H. T., Farley, M. M., Craig, A. S., Mohle‐Boetani, J. C., Harrison, L. H., Petit, S., Lynfield, R., Thomas, A. R., Zansky, S. M., Gershman, K. A., et al. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318180b3b9 · Cited by 193
Self-citation
Incidence, Etiology, and Outcome of Bacterial Meningitis in Infants Aged <90 Days in the United Kingdom and Republic of Ireland: Prospective, Enhanced, National Population-Based Surveillance
Okike, I. O., Johnson, A. P., Henderson, K. L., Blackburn, R. M., Müller‐Pebody, B., Ladhani, S. N., Anthony, M., Ninis, N., Heath, P. T., for the neoMen Study Group, et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu514 · Cited by 181
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial
Madhi, S. A., Cutland, C., Jose, L., Koen, A. L., Govender, N., Wittke, F., Olugbosi, M., Meulen, A. S.-T., Baker, S. A., Dull, P. M., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00152-3 · Cited by 167
Self-citation
Incidence and Severity of Invasive Streptococcus pneumoniae, Group A Streptococcus, and Group B Streptococcus Infections Among Pregnant and Postpartum Women
Deutscher, M., Lewis, M., Zell, E. R., Taylor, T. H., Beneden, C. V., Schrag, S. J., & for the Active Bacterial Core Surveillance Team (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir325 · Cited by 165
Self-citation
Incidence of invasive group B streptococcal disease and pathogen genotype distribution in newborn babies in the Netherlands over 25 years: a nationwide surveillance study
Bekker, V., Bijlsma, M. W., van de Beek, D., Kuijpers, T. W., & ENDE, A. V. D. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70919-3 · Cited by 161
Group B streptococcal infections
Edwards, M. S. (1990) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199010000-00040 · Cited by 155
Remington and Klein's Infectious Diseases of The Fetus and Newborn Infant
Garg, S., & Tin, W. (2015) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2015.09.002 · Cited by 153
Group B Streptococcal Infections
Randis, T. M., Baker, J. A., & Ratner, A. J. (2017) · Pediatrics in Review · doi:10.1542/pir.2016-0127 · Cited by 148
Capsular Switching in Group B Streptococcus CC17 Hypervirulent Clone: A Future Challenge for Polysaccharide Vaccine Development
Bellais, S., Six, A., Fouet, A., Longo, M., Dmytruk, N., Glaser, P., Trieu‐Cuot, P., & Poyart, C. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis605 · Cited by 147
Level of Maternal IgG Anti–Group B Streptococcus Type III Antibody Correlated with Protection of Neonates against Early‐Onset Disease Caused by This Pathogen
Lin, F. C., Weisman, L. E., Azimi, P. H., Philips, J. B., Clark, P., Regan, J. A., Rhoads, G. G., Frasch, C. E., Gray, B. M., Troendle, J. F., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/422756 · Cited by 143
Maternal group B Streptococcus ‐related stillbirth: a systematic review
Nan, C., Dangor, Z., Cutland, C., Edwards, M., Madhi, S. A., & Cunnington, M. C. (2015) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.13527 · Cited by 139
Self-citation
Maternal Antibody at Delivery Protects Neonates From Early Onset Group B Streptococcal Disease
Baker, C. J., Carey, V. J., Rench, M. A., Edwards, M. S., Hillier, S. L., Kasper, D. L., & Platt, R. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit549 · Cited by 138
Self-citation
Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants
Madhi, S. A., Dangor, Z., Heath, P. T., Schrag, S. J., Izu, A., Meulen, A. S.-T., & Dull, P. M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.029 · Cited by 134
Self-citation
Group B Streptococcus -hemolysin/Cytolysin Breaches Maternal-Fetal Barriers to Cause Preterm Birth and Intrauterine Fetal Demise in Vivo
Randis, T. M., Gelber, S. E., Hooven, T. A., Abellar, R. G., Akabas, L. H., Lewis, E. L., Walker, L., Byland, L. M., Nizet, V., & Ratner, A. J. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu067 · Cited by 133
Level of Maternal Antibody Required to Protect Neonates against Early‐Onset Disease Caused by Group B Streptococcus Type Ia: A Multicenter, Seroepidemiology Study
Lin, F. C., Philips, J. B., Azimi, P. H., Weisman, L. E., Clark, P., Rhoads, G. G., Regan, J. A., Concepcion, N. F., Frasch, C. E., Troendle, J. F., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/323350 · Cited by 133
Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial
Heyderman, R. S., Madhi, S. A., French, N., Cutland, C., Ngwira, B. M., Kayambo, D., Mboizi, R. B., Koen, A. L., Jose, L., Olugbosi, M., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00484-3 · Cited by 133
Self-citation
Global Advisory Committee on Vaccine Safety, 10-11 June 2004.
(2004) · PubMed · Cited by 120
Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya
Seale, A. C., Koech, A. C., Sheppard, A. E., Barsosio, H. C., Langat, J., Anyango, E., Mwakio, S., Mwarumba, S., Morpeth, S. C., Anampiu, K., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.67 · Cited by 118
Self-citation
High Incidence of Invasive Group B Streptococcal Infections in HIV-Exposed Uninfected Infants
Epalza, C., Goetghebuer, T., Hainaut, M., Prayez, F., Barlow, P., Dediste, A., Marchant, A., & Lévy, J. (2010) · PEDIATRICS · doi:10.1542/peds.2010-0183 · Cited by 114
Group B streptococcal epidemiology and vaccine needs in developed countries
Melin, P., & Efstratiou, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.012 · Cited by 98
Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine
Donders, G. G. G., Halperin, S. A., Devlieger, R., Baker, S. A., Forte, P., Wittke, F., Slobod, K. S., & Dull, P. M. (2016) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000001190 · Cited by 97
Risk Factors for Neonatal Sepsis and Perinatal Death Among Infants Enrolled in the Prevention of Perinatal Sepsis Trial, Soweto, South Africa
Schrag, S. J., Cutland, C., Zell, E. R., Kuwanda, L., Buchmann, E., Velaphi, S., Groome, M. J., & Madhi, S. A. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31825c4b5a · Cited by 80
Self-citation
Risk factors for Group B Streptococcus colonisation and disease in Gambian women and their infants
Doaré, K. L., Jarju, S., Darboe, S., Warburton, F. G., GORRINGE, A. R., Heath, P. T., & Kampmann, B. (2016) · Journal of Infection · doi:10.1016/j.jinf.2015.12.014 · Cited by 75
Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa
Kim, S.-Y., Russell, L. B., Park, J., Verani, J. R., Madhi, S. A., Cutland, C., Schrag, S. J., & Sinha, A. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.01.062 · Cited by 70
Self-citation
A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women
Leroux-Roels, G. G., Maes, C., Willekens, J., Boever, F. D., de Rooij, R., Martell, L., Bedell, L., Wittke, F., Slobod, K. S., & Dull, P. M. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.044 · Cited by 68
Increased Risk for Group B Streptococcus Sepsis in Young Infants Exposed to HIV, Soweto, South Africa, 2004–20081
Cutland, C., Schrag, S. J., Thigpen, M. C., Velaphi, S., Wadula, J., Adrian, P. V., Kuwanda, L., Groome, M. J., Buchmann, E., & Madhi, S. A. (2015) · Emerging infectious diseases · doi:10.3201/eid2104.141562 · Cited by 67
Self-citation
Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants
Dangor, Z., Kwatra, G., Izu, A., Adrian, P. V., Cutland, C., Velaphi, S., Ballot, D. E., Reubenson, G., Zell, E. R., Lala, S. G., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.019 · Cited by 62
Self-citation
Twenty-five years of the WHO vaccines prequalification programme (1987–2012): Lessons learned and future perspectives
Dellepiane, N., & Wood, D. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.11.066 · Cited by 61
Association between low concentrations of antibodies to protein α and Rib and invasive neonatal group B streptococcal infection
Larsson, C., Lindroth, M., Nordin, P., Stålhammar‐Carlemalm, M., Lindahl, G., & Krantz, I. (2006) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/adc.2005.090472 · Cited by 61
Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7–9th Sep 2015
Giersing, B. K., Modjarrad, K., Kaslow, D. C., Moorthy, V., Bavdekar, A., Cichutek, K., Cravioto, A., Fritzell, B., Graham, B. S., Karron, R. A., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.078 · Cited by 54
Self-citation
Disease Burden of Group B Streptococcus Among Infants in Sub-Saharan Africa: A Systematic Literature Review and Meta-analysis
Sinha, A., Russell, L., Tomczyk, S., Verani, J., Schrag, S., Berkley, J., Mohammed, M., Sigaúque, B., & Kim, S.-Y. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001233 · Cited by 54
Self-citation
Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine
Larsson, C., Stålhammar‐Carlemalm, M., & Lindahl, G. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00218-7 · Cited by 51
Immunogenicity and protective efficacy of the alpha C protein of group B streptococci are inversely related to the number of repeats
Gravekamp, C., Kasper, D. L., Michel, J. L., Kling, D. E., Carey, V. J., & Madoff, L. C. (1997) · Infection and Immunity · doi:10.1128/iai.65.12.5216-5221.1997 · Cited by 50
Vaccines to prevent neonatal GBS infection
Paoletti, L. (2002) · Seminars in Neonatology · doi:10.1016/s1084-2756(02)90114-4 · Cited by 49
Regulatory considerations in the clinical development of vaccines indicated for use during pregnancy
Roberts, J. N., & Gruber, M. F. (2015) · Vaccine · doi:10.1016/j.vaccine.2014.12.068 · Cited by 47
Maternal Antibody Transfer in Baboons and Mice Vaccinated with a Group B Streptococcal Polysaccharide Conjugate
Paoletti, L. C., Pinel, J., Kennedy, R. C., & Kasper, D. L. (2000) · The Journal of Infectious Diseases · doi:10.1086/315285 · Cited by 40
New WHO guidance on prevention and treatment of maternal peripartum infections
Bonet, M., Oladapo, O. T., Khan, D. N., Mathai, M., & Gülmezoglu, A. M. (2015) · The Lancet Global Health · doi:10.1016/s2214-109x(15)00213-2 · Cited by 39
Vaccines to prevent neonatal GBS infection
Paoletti, L. C., & Madoff, L. C. (2002) · Seminars in Neonatology · doi:10.1053/siny.2002.0114 · Cited by 35
Recurrence of Group B Streptococci Colonization in Subsequent Pregnancy
TURRENTINE, M. A., & Ramirez, M. M. (2008) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31817f5cb9 · Cited by 34
Using the impact of pneumococcal vaccines on nasopharyngeal carriage to aid licensing and vaccine implementation; A Pneumocarr meeting report March 27–28, 2012, Geneva
Goldblatt, D., Ramakrishnan, M., & O'Brien, K. L. O. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.06.040 · Cited by 24
Mind the gap: jumping from vaccine licensure to routine use
O’Brien, K. L., Binka, F. N., Marsh, K., & Abramson, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30394-4 · Cited by 22
Prevalence, Serotype Distribution and Mortality Risk Associated With Group B Streptococcus Colonization of Newborns in Rural Bangladesh
Islam, M. S., Saha, S. K., Islam, M., Modak, J. K., Shah, R., Talukder, R. R., Arifeen, S. E., Baqui, A. H., Darmstadt, G. L., & Mullany, L. C. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001306 · Cited by 19
Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries
Dellepiane, N., Akanmori, B. D., Gairola, S., Jadhav, S. S., Parker, C., Rodriguez, C., & Srivastava, S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ491 · Cited by 15
Experimental vaginal colonization and mother-infant transmission of group B streptococci in rats
Ancona, R. J., & Ferrieri, P. (1979) · Infection and Immunity · doi:10.1128/iai.26.2.599-603.1979 · Cited by 14
Ascending group B streptococcal genital infection in the rabbit model
McDuffie, R. S., & Gibbs, R. S. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70153-9 · Cited by 13
The impact of universal newborn hearing screening
Harrop‐Griffiths, K. (2015) · Archives of Disease in Childhood · doi:10.1136/archdischild-2014-307867 · Cited by 13
Women Receiving Group B Streptococcus Serotype III Tetanus Toxoid (GBS III-TT) Vaccine Have Reducesd Vaginal and Rectal Acquisition of GBS Type III
Hillier, S. L. (2009) · 47th Annual Meeting · Cited by 12
Ethical considerations for designing GBS maternal vaccine efficacy trials in low-middle income countries
White, A., & Madhi, S. A. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.108 · Cited by 12
Self-citation
Profile: PATH’s Vaccine Development Global Program
Boslego, J. W. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21033 · Cited by 2

Research works printed but not linked: 3

O'Sullivan, 2016, Group B Streptococcal (GBS) disease in UK ad Irish infants younger than 90 days of age in 2014–15. Paper presented at the Royal College of Paediatrics and Child Health, 26–28 April, 2016, Liverpool, UK Abstract published, Arch Dis Child, 101, 1
Akanmori, 2015, The African Vaccine Regulatory Forum (AVAREF): a platform for collaboration in a public health emergency, WHO Drug Inform, 29, 127
World Health Organization, 2016, Global Advisory Committee on vaccine safety 15–16 June 2016, Wkly Epidemiol Rec, 28, 341

Sorted by citations

A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children
Seale, A. C., Bianchi-Jassir, F., Russell, N. J., Kohli-Lynch, M., Tann, C. J., Hall, J., Madrid, L., Blencowe, H., Cousens, S., Baker, C. J., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix664 · Cited by 511
Self-citation
Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015
Nanduri, S. A., Petit, S., Smelser, C. B., Apostol, M. M., Alden, N. B., Harrison, L. H., Lynfield, R., Vagnone, P. S., Burzlaff, K. E., Spina, N., et al. (2019) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2018.4826 · Cited by 388
Self-citation
Group B Streptococcal Colonization, Molecular Characteristics, and Epidemiology
Shabayek, S., & Spellerberg, B. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00437 · Cited by 302
Epidemiology of Invasive Group B Streptococcal Infections Among Nonpregnant Adults in the United States, 2008-2016
Watkins, L. F., McGee, L., Schrag, S. J., Beall, B., Jain, J. H., Pondo, T., Farley, M. M., Harrison, L. H., Zansky, S. M., Baumbach, J., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.7269 · Cited by 210
Self-citation

See all 105

Authors: Kobayashi, M., Schrag, S. J., Alderson, M. R., Madhi, S. A., Baker, C. J., Sobanjo-ter Meulen, A., Kaslow, D. C., Smith, P. G., Moorthy, V. S., & Vekemans, J.
Affiliations: Centers for Disease Control and Prevention (US)
Program for Appropriate Technology in Health (US)
University of the Witwatersrand (ZA)
Baylor College of Medicine (US)
London School of Hygiene & Tropical Medicine (GB)
World Health Organization (CH)
Corresponding author: Vekemans, Johan
ORCID: Kobayashi, Miwako
Schrag, Stephanie J.
Alderson, Mark R.
Madhi, Shabir A.
Kaslow, David C.
Smith, Peter G.
Moorthy, Vasee S.
Vekemans, Johan
Venue: Vaccine
Publisher: Elsevier BV
Published: 2019-11
Volume: 37
Issue: 50
Pages: 7307-7314
ISSN: 0264-410X (ISSN-L)
DOI: 10.1016/j.vaccine.2016.12.029
PMC: PMC6892266
OpenAlex: W2561215256
Cited by: 105
References: 55
Citations by year: 2026: 6 · 2025: 8 · 2024: 6 · 2023: 9 · 2022: 12 · 2021: 16 · 2020: 11 · 2019: 11
FWCI: 1.79
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Vaccine (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
Lincoln (University of Nebraska) (submittedVersion, cc-by)
Funders: Novartis/GSK
Bill & Melinda Gates Foundation (OPP1134011)
Topics: Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and Maternal Infections
Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
Keywords: Streptococcus agalactiae, maternal immunization, intrapartum antibiotic prophylaxis, neonatal sepsis, neonatal meningitis, stillbirth, transplacental antibody transfer, serotype distribution, disease burden, correlates of protection, antibody assays, vaccine licensure, low- and middle-income countries
MeSH terms: Animals, Clinical Trials as Topic, Female, Humans, Pregnancy, Pregnancy Complications, Infectious, Streptococcal Infections, Streptococcus agalactiae, Vaccination, World Health Organization, Infectious Disease Transmission, Vertical, Streptococcal Vaccines, Stillbirth

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks